Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI resistant renal cancer

PURPOSE: VEGFR2 tyrosine kinase inhibition (TKI) is a valuable treatment approach for patients with metastatic RCC. However, resistance to treatment is inevitable. Identification of novel targets could lead to better treatment for both patients with TKI naïve or resistant RCC. EXPERIMENTAL DESIGN: I...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Zhang, Liang, Wang, Xiaoen, Bullock, Andrea J., Callea, Marcella, Shah, Harleen, Song, Jiaxi, Moreno, Kelli, Visentin, Barbara, Deutschman, Douglas, Alsop, David C., Atkins, Michael B., Mier, James W., Signoretti, Sabina, Bhasin, Manoj, Sabbadini, Roger A., Bhatt, Rupal S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4419371/
https://ncbi.nlm.nih.gov/pubmed/25589614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2031
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge